Does Whole-Body 2-[ 18 F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Have an Advantage Over Thoracic Positron Emission Tomography for Staging Patients With Lung Cancer?
Authors:
- Suzanne L. AquinoSASuzanne L. Aquino
- Alan J. FischmanAFAlan J. Fischman
- 1 September 2004
- Vol. 126 (3) , 755-760
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- The Noninvasive Staging of Non-small Cell Lung Cancer*Chest, 2003
- Mediastinal Lymph Node Sampling Following Positron Emission Tomography With Fluorodeoxyglucose Imaging in Lung Cancer StagingChest, 2001
- High rate of detection of unsuspected distant metastases by PET in apparent Stage III non–small-cell lung cancer: implications for radical radiation therapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2001
- Preoperative Staging of Non–Small-Cell Lung Cancer with Positron-Emission TomographyNew England Journal of Medicine, 2000
- Staging Non-Small Cell Lung Cancer with Whole-Body PETRadiology, 1999
- Detection of extrathoracic metastases by positron emission tomography in lung cancerThe Annals of Thoracic Surgery, 1998
- Pretreatment Evaluation of Non–Small-cell Lung CancerAmerican Journal of Respiratory and Critical Care Medicine, 1997
- Revisions in the International System for Staging Lung CancerChest, 1997
- Staging non—small cell lung cancer by whole-body positron emission tomographic imagingThe Annals of Thoracic Surgery, 1995
- Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer.Thorax, 1988